Using IL-4, Benedetti et al. demonstrated the efficacy of IL-4 as a tumor-combating cytokine, and also showed that delivering it specifically via NSCs led to improved survival durations compared to introducing IL-4 using other methods, such as retroviral transfer. Here, IL4 is linked to neoplasm.